AnaptysBio (NASDAQ: ANAB) closed more than 10% higher on Friday. This followed news that a drug the company partnered on has received a positive opinion from an important multinational health agency.
On Friday, the European Union's (EU) European Medicines Agency's Committee for Medicinal Products for Human Use recommended that the EU grant conditional marketing authorization for Jemperli (dostarlimab). This is an immunotherapy drug being developed by GlaxoSmithKline (NYSE: GSK) that treats recurrent or advanced endometrial cancer.
GlaxoSmithKline, a global pharmaceutical company, has partnered with immunotherapy specialist AnaptysBio on that drug and several other pipeline medicines. In all cases, AnaptysBio-generated antibodies are being utilized in those treatments.
For further details see:
Why AnaptysBio Was a Stock Market Star on Friday